|
|
Post by sayhey24 on Feb 27, 2024 16:04:10 GMT -5
|
|
|
|
Post by parrerob on Feb 27, 2024 16:06:59 GMT -5
Coll & Service 17 M$
Afrezza not bad
Wow
|
|
|
|
Post by BlueCat on Feb 27, 2024 16:36:15 GMT -5
Is there going to be the usual shoutbox today when the call starts?
|
|
|
|
Post by liane on Feb 27, 2024 16:39:54 GMT -5
yes
|
|
|
|
Post by cppoly on Feb 29, 2024 7:35:03 GMT -5
I think this is a really good slide from the conference call. These are the expected milestones for 2024.  |
|
|
|
Post by parrerob on Feb 29, 2024 7:49:53 GMT -5
Right.... it is the first time we have a clear timing for next milestones (some of that very close in time).
Missing only Cipla/India milestone but it was discussed in the speach
|
|
|
|
Post by celo on Mar 1, 2024 10:58:01 GMT -5
I think this is a really good slide from the conference call. These are the expected milestones for 2024. View AttachmentWithin that slide is the "high speed fill/finish line", which Mike said was just completed and will allow for a much higher run rate for latter half of Q1 going into Q2. Then in Q2 the "new drying/spraying capacity" should even further the output. Tyvaso revs didn't see much qtr/qtr increase but that should change most likely this qtr but for sure next. This will allow a higher revs and higher profit. |
|
|
|
Post by prcgorman2 on Mar 1, 2024 11:54:38 GMT -5
I think this is a really good slide from the conference call. These are the expected milestones for 2024. View AttachmentWithin that slide is the "high speed fill/finish line", which Mike said was just completed and will allow for a much higher run rate for latter half of Q1 going into Q2. Then in Q2 the "new drying/spraying capacity" should even further the output. Tyvaso revs didn't see much qtr/qtr increase but that should change most likely this qtr but for sure next. This will allow a higher revs and higher profit. It's a good thing when the more you make the more you make. |
|
|
|
Post by mango on Mar 1, 2024 12:28:38 GMT -5
Right.... it is the first time we have a clear timing for next milestones (some of that very close in time). Missing only Cipla/India milestone but it was discussed in the speach The Afrezza Cipla/India milestone is in the 2024 Milestones graphic. It’s in the top right, should expect India regulatory decision 4Q this year. And when we look at the Milestones timeline for this year alone, man…it’s a lot! Clofazimine and nintedanib could be significant growth assets for the company if success in the trials. And very exciting upcoming Afrezza trial data that actually carry enough weight to change the standards of care. |
|
|
|
Post by radgray68 on Mar 1, 2024 13:57:18 GMT -5
I like that Mike actually mentioned possibly doubling the salespeople. That’ll cause an inflection in scripts.
|
|
|
|
Post by uvula on Mar 1, 2024 15:07:32 GMT -5
I like that Mike actually mentioned possibly doubling the salespeople. That’ll cause an inflection in scripts. Hate to inject a dose of reality into our new found optimizm, but here goes. If we don't solve the insurance and cost issues, a doubling of the salesforce will do nothing but increase our burn rate. |
|
|
|
Post by mango on Mar 1, 2024 15:20:33 GMT -5
I like that Mike actually mentioned possibly doubling the salespeople. That’ll cause an inflection in scripts. Hate to inject a dose of reality into our new found optimizm, but here goes. If we don't solve the insurance and cost issues, a doubling of the salesforce will do nothing but increase our burn rate. Hopefully the trial data will change the SoC in a significant way that it solves the insurance problem. |
|
|
|
Post by prcgorman2 on Mar 1, 2024 15:52:24 GMT -5
I like that Mike actually mentioned possibly doubling the salespeople. That’ll cause an inflection in scripts. Hate to inject a dose of reality into our new found optimizm, but here goes. If we don't solve the insurance and cost issues, a doubling of the salesforce will do nothing but increase our burn rate. Agree with mango. Also, both Mike and Steve described that the results from the INHALE-1 (pump/switch) and INHALE-3 (Pediatrics) trials are what they're counting on to inform their marketing decision making. Mike specifically said, "we could double the quantity of salespeople..." and went on to say they needed to have data to help them to know what the next steps should be in terms of additional trials, etc. I really liked hearing that because, well, I like informed decision making, but also because it showed a willingness to continue to buttress current information available with additional information to continue to develop a current portfolio influential to prescription writers at least, if not also ADA SoC and insurance providers.
The bottom-line is they're not shooting in the dark, and they're not afraid of increasing the sales force when they can be confident the time is right for that move.
|
|
|
|
Post by sayhey24 on Mar 1, 2024 22:16:32 GMT -5
Hate to inject a dose of reality into our new found optimizm, but here goes. If we don't solve the insurance and cost issues, a doubling of the salesforce will do nothing but increase our burn rate. Agree with mango. Also, both Mike and Steve described that the results from the INHALE-1 (pump/switch) and INHALE-3 (Pediatrics) trials are what they're counting on to inform their marketing decision making. Mike specifically said, "we could double the quantity of salespeople..." and went on to say they needed to have data to help them to know what the next steps should be in terms of additional trials, etc. I really liked hearing that because, well, I like informed decision making, but also because it showed a willingness to continue to buttress current information available with additional information to continue to develop a current portfolio influential to prescription writers at least, if not also ADA SoC and insurance providers.
The bottom-line is they're not shooting in the dark, and they're not afraid of increasing the sales force when they can be confident the time is right for that move.
I sure hope Mike does not double the sales force again until we know what we are doing. We have been through this 4X now. We can't keep doing the same thing over and over. Nothing is going to change as long as the PBMs are in control. For the kids there are set number of pediatric centers that they need to target - I think the number is 40. At most we need 4 sales reps for those forty sites. Mike has to be laser focused right now and figure out the cost/insurance issue. Its time to put the big boy pants on. Few T2s will get insurance. Some T1s will but as Ginger V. found out it won't be easy. Lets assume Mike figures out the cost issue and now anyone can buy for $35 with no pre auths. Then the answer is really easy. Its the afrezza GLP study Mike mentioned with an arm of afrezza head to head against the GLPs. If he does not figure out the cost issue then the best he has is a portion of the T1 market who get through the insurance denial process. Afrezza remains a niche drug. Doing a T2 study would make ZERO sense. At that point the money is better spent on lobbying the ADA for SoC T1 changes and then hope for better T1 insurance coverage. |
|
|
|
Post by prcgorman2 on Mar 2, 2024 9:05:53 GMT -5
Luckily “figuring out” Afrezza marketing is no longer urgent, but remains important. Lowering the cost and attaining better insurance coverage don’t matter at all, period, full stop, unless there are going to be significantly more prescriptions written for Afrezza. The cost and insurance are significant issues once you can get prescribers on board. As agedhippie, stevil, matt, and others, have explained, and Dr. Kendall’s experiences prove, the toughest nut to crack is gaining acceptance from doctors prescribing insulin, and the surest way of accomplishing that, we’re told, is through full-scale, multi-arm, clinical trials. This is what makes the pediatric trial so critically important. If successful it will go a long ways to prove both SAFETY (safety SAFETY SAFETY) and superiority (not non-inferior). Both of those are powerhouse motivations. Prove those, get prescribers, interested, and then go after cost, insurance, and sales force. That appears to be the path MannKind is taking, so I’m patiently waiting (still) to see if that tried-and-true, decades-old, approach yields the results we so want to see.
|
|
